Design, development and performance of a novel multidose dry-powder inhaler.
The authors describe the design and development of a breath-actuated multidose dry-powder inhaler and summarize the in vitro and in vivo data demonstrating its robustness and performance in the laboratory and during clinical use. Drugs for the treatment of asthma--including budesonide, beclomethasone dipropionate and salbutamol--when formulated with lactose powder as a carrier and dispensed via this device, have exhibited clinical efficacy and safety profiles comparable with standard pressurized metered-dose inhalers and dry-powder formulations.
Parry-Billings
M
M
R&D at Innovata Biomed Ltd, Respiratory Division of ML Laboratories plc, St Albans, UK. mparryb@aol.com
Boyes
R N
RN
Clisby
L M
LM
Braithwaite
P
P
Williams
S
S
Harper
A E
AE
D018927:Anti-Asthmatic Agents / Q000008:administration & dosage*; D004867:Equipment Design; D006801:Humans; D009330:Nebulizers and Vaporizers; D011208:Powders
D018927:Anti-Asthmatic Agents; D011208:Powders